Despite Negative FDA Panel, Needham & Company Sees Approval of Sarepta's (SRPT) Eteplirsen as Early as Next Year
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 17.73 -0.45 (2.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.18 | 52 Week High | $63.73 | |||
| Open | $17.94 | 52 Week Low | $8.00 | |||
| Day High | $18.12 | P/E | N/A | |||
| Day Low | $17.16 | EPS | $-5.69 | |||
| Volume | 1,285,443 | |||||
